一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-045 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 近日，公司与广发银行股份有限公司昆明万宏支行签订了《广发银行"物华添宝"W 款 2025 年第 680 期定制版人民币结构性存款（挂钩黄金现货看涨阶梯式）（昆明分行）合同》，现将 有关情况公告如下： | 签约银行 | 产 ...

一心为民 全心服务 关于全资子公司河南鸿翔一心堂药业有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司")于 2025 年 5 月 21 日召开 2024 年年度股 东会，审议通过《关于同意子公司向相关银行申请综合授信额度并为其提供担保的议案》，同 意公司担保下属子公司向相关银行申请综合授信共计 2 亿元，用于子公司融资业务，具体额度 在不超过 2 亿元的金额上限内以银行授信为准，以上综合授信在一年内以银行授信为准。《关 于同意子公司向相关银行申请综合授信额度并为其提供担保的公告》详见公司指定信息披露媒 体《证券时报》《中国证券报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）。 二、担保事项进展情况 近日公司与上海浦东发展银行股份有限公司郑州分行签署了《最高额保证合同》，为全资 子公司河南鸿翔一心堂药业有限公司（以下简称"河南一心堂"）提供连带责任保证，担保的 主债权本金余额为最高额人民币 2,000 万元。 上述担保在已经审议的预计担保 ...

Core Insights - YaoXingTang has experienced significant growth since its IPO on July 2, 2014, with its market capitalization increasing from 4.573 billion yuan to 9.434 billion yuan, reflecting the expansion of the retail pharmacy industry [1] - Despite the growth in scale, the company's profitability has notably declined in recent years, with a cumulative profit decrease of 61.61% from 2.97 billion yuan in 2014 to 1.14 billion yuan in 2024 [3][4] Business Overview - YaoXingTang's main business segments include retail pharmacy chains and pharmaceutical wholesale, with Western medicine accounting for the largest share of revenue at 75.56%, followed by traditional Chinese medicine at 8.48% [3] - The company has maintained profitability over the years, with no annual losses since its listing, achieving profit growth in 9 out of 11 years, representing 81.82% of the time [3] Financial Performance - Revenue has shown an upward trend, increasing from 12.656 billion yuan in 2020 to 18 billion yuan in 2024, although the growth rate has slowed [4] - In contrast, net profit has significantly declined from 790 million yuan in 2020 to 114 million yuan in 2024, with consecutive negative growth in 2023 and 2024 [4] Market Capitalization - The peak market capitalization of YaoXingTang reached 29.869 billion yuan in April 2021, with the stock price rising to 50.1 yuan, but by July 1, 2024, the market cap had dropped to 9.434 billion yuan, representing a loss of 20.435 billion yuan or 68.42% [6]

Core Viewpoint - The retail pharmacy industry is experiencing accelerated closures, with a total of 39,228 stores shut down in 2024, leading to a potential recovery in customer traffic and profit margins for leading pharmacies post-industry consolidation [1][2]. Group 1: Industry Trends - The number of closed pharmacies in 2024 is reported as follows: Q1 - 6,778, Q2 - 8,791, Q3 - 9,545, Q4 - 11,414, indicating a significant acceleration in closures, with a net decrease of 3,395 stores in Q4 alone [1]. - The industry is facing a severe environment for small and medium-sized pharmacies due to weak consumer power, medical insurance cost control, and enhanced regulatory measures, leading to a consolidation trend [1]. Group 2: Market Opportunities - Leading retail pharmacies are expected to benefit from a "siphon effect" in customer traffic due to their first-mover advantage in local market outpatient coordination, which may enhance customer spending and overall performance [2]. - The implementation of outpatient coordination policies is anticipated to increase medical insurance spending and related product consumption, potentially raising average transaction values [2]. Group 3: Strategic Initiatives - Leading pharmacies are actively exploring diversified operations and innovative store management to enhance market competitiveness, such as transforming into service complexes and creating new store formats [3]. - Examples include Yifeng Pharmacy's transition towards service complexes and Yixin Hall's development of new store formats to attract more customers [3]. Group 4: Recommended Stocks - Companies that are expected to benefit from the industry cycle and demonstrate superior management capabilities include Yifeng Pharmacy (603939.SH) and Daclin (603233.SH) as recommended stocks, while beneficiaries include Laobaixing (603883.SH), Yixin Hall (002727.SZ), and Jianzhijia (605266.SH) [4].

一心为民 全心服务 关于使用部分暂时闲置 2018 年公开发行可转换公司债券 募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置2018年公开发行可转换公司债券募集资金进行现金管理的议 案》，同意公司使用额度不超过人民币3.25亿元的2018年公开发行可转换公司债券的暂时闲置 募集资金进行现金管理（包括但不限于购买一年期以内的固定收益型或保本浮动收益型理财产 品、大额存单、定期存款、通知存款、协定存款等），以上额度为在投资期限内任一时点的现 金管理金额(含前述投资的收益进行再投资的相关金额)不超过3.25亿元人民币。在上述额度内， 资金可以滚动使用，在额度范围内授权董事长具体办理实施相关事项。独立董事、保荐机构对 上述议案发表了审查意见。 近日，公司与上海浦东发展银行股份有限公司昆明分行签订了《对公结构性存款产品合同》， 于 2025 年 6 月 30 日使用部分暂时闲置募集资金人民币 8,900 万元购买 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-043 号 一心堂药业集团股份有限公司 一心为民 全心服务 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 近日，公司与中国建设银行股份有限公司昆明滇龙支行签订了《中国建设银行人民币单位 协定存款合同》，现将有关情况公告如下： | 签约银 行名称 | 产品名称 | 基本存款 额度（万 | 收益类型 | 合同起始日 | 合同到期日 | 计息方式 | | --- ...

Core Viewpoint - Yixin Pharmaceutical Group Co., Ltd. has approved an investment by its wholly-owned subsidiary, Guizhou Hongxiang Yixintang Pharmaceutical Chain Co., Ltd., to acquire land use rights and associated structures for a total investment of RMB 32.8 million [2]. Group 1: Investment Details - The investment involves acquiring land use rights and buildings located at No. 13, Longdongbao Food Industrial Park, Nanning District, Guiyang City, which has a building area of 17,521.25 square meters [2]. - The total area of the land parcel is 26,122.49 square meters, designated for industrial use [2][4]. - The land use rights are granted for a period starting from January 15, 2014, to January 15, 2064 [4]. Group 2: Legal and Administrative Aspects - The land use rights have been officially registered, and the company has obtained the "People's Republic of China Real Estate Property Certificate" for the property [2]. - The rights are classified as state-owned construction land use rights with a transfer nature [2].

一心为民 全心服务 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2024年12月26日召开第六届董事会第 七次临时会议，审议通过《关于同意全资子公司贵州鸿翔一心堂医药连锁有限公司对外投资取 得土地使用权及其地上附着物的议案》，同意全资子公司贵州鸿翔一心堂医药连锁有限公司（以 下简称"贵州一心堂"）以自有资金人民币3,280万元投资取得贵州方鸿实业有限责任公司位于 贵阳市双龙新区跨越大道南明区龙洞堡食品工业园A区13号地块分割出来的土地使用权及其地 上附着物。具体内容详见公司2024年12月28日在指定信息披露媒体《证券时报》《中国证券报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）刊登的《关于同意全资子公司贵州鸿翔一心 堂医药连锁有限公司对外投资取得土地使用权及其地上附着物的公告》（公告编号：2024-163 号）。 近日，贵州一心堂已完成土地使用权变更登记事项，并取得坐落于南明区龙洞堡食品工业 园G(13)33号地块的《中华人民共和国不动产权证书》及其地上附着物（建筑物面积17521.2 ...

A股医药商业板块水下拉起，一心堂封板涨停，漱玉平民、健之佳、华人健康、第一医药、益丰药房等 跟涨。 ...

Group 1: Store Transformation and Impact - The selection of existing store locations is based on the target demographics of each region, with a focus on transforming suitable stores for new product lines [2] - The non-pharmaceutical product sales ratio has increased post-transformation, but this does not negatively impact pharmaceutical sales, as the latter remains the core business [3] - Data from sample stores indicate that after transformation, transaction frequency has increased, leading to higher sales and customer traffic [4] Group 2: Product Categories and Profitability - Different product categories have varying profit margins, with both high and low-margin items present in each category [5] - Transformed stores have reported higher profit margins post-renovation, with increased customer traffic and sales driven by innovative products [6] Group 3: Cost and Training Considerations - The transformation of stores does not significantly increase fixed asset or labor costs, as display optimization and collaboration with suppliers help manage expenses [7] - Training for staff on innovative product sales is conducted collaboratively by suppliers and the company's management to ensure employees are well-informed [7]